Bryostatins: biological context and biotechnological prospects by Trindade-Silva, Amaro E. et al.
Roger Williams University 
DOCS@RWU 
Arts & Sciences Faculty Publications Arts and Sciences 
2010 
Bryostatins: biological context and biotechnological prospects 
Amaro E. Trindade-Silva 
Grace E. Lim-Fong 
Koty H. Sharp 
Roger Williams University, ksharp@rwu.edu 
Follow this and additional works at: https://docs.rwu.edu/fcas_fp 
 Part of the Biology Commons, Marine Biology Commons, and the Microbiology Commons 
Recommended Citation 
Trindade-Silva, A.E., Lim-Fong, G.E., Sharp, K.H. & Haygood, M.G. (2010). Bryostatins: biological context 
and biotechnological prospects. Current Opinion in Biotechnology, 21(6). 
This Article is brought to you for free and open access by the Arts and Sciences at DOCS@RWU. It has been accepted 
for inclusion in Arts & Sciences Faculty Publications by an authorized administrator of DOCS@RWU. For more 
information, please contact mwu@rwu.edu. 
Bryostatins: Biological context and biotechnological prospects
Amaro E. Trindade-Silva1,*, Grace E. Lim-Fong2,*, Koty H. Sharp3, and Margo G. Haygood4
Amaro E. Trindade-Silva: amarots@iqsc.usp.br; Grace E. Lim-Fong: glim@rmc.edu; Koty H. Sharp: 
kotysharp@gmail.com; Margo G. Haygood: haygoodm@ebs.ogi.edu
1Instituto de Química de São Carlos, Universidade de São Paulo CP 780, CEP 13560-970, São 
Carlos, SP, Brazil
2Department of Biology, Randolph-Macon College, 304 Caroline Street Ashland, VA 23005, USA
3Ocean Genome Legacy 240 County Road Ipswich, MA 01970, USA
4Division of Environmental and Biomolecular Systems, Institute of Environmental Health, Oregon 
Health and Science University, West Campus, 20000 NW Walker Road, Mail Code OGI 100, 
Beaverton, OR 97006-8921 USA
Summary of recent advances
Bryostatins are a family of protein kinase C modulators that have potential applications in 
biomedicine. Found in miniscule quantities in a small marine invertebrate, lack of supply has 
hampered their development. In recent years, bryostatins have been shown to have potent 
bioactivity in the central nervous system, an uncultivated marine bacterial symbiont has been 
shown to be the likely natural source of the bryostatins, the bryostatin biosynthetic genes have 
been identified and characterized, and bryostatin analogues with promising biological activity 
have been developed and tested. Challenges in development of bryostatins for biomedical and 
biotechnological application include the cultivation of the bacterial symbiont and heterologous 
expression of bryostatin biosynthesis genes. Continued exploration of the biology and the 
symbiotic origin of the bryostatins presents promising opportunities for discovery of additional 
bryostatins, and new functions for bryostatins.
Introduction
Microbial symbionts have often been suggested to be the source of natural products isolated 
from marine invertebrates, usually based on structural similarity of compounds to known 
microbial secondary metabolites. Structural similarity is a valid argument only for 
structurally complex molecules assembled through many biosynthetic steps. The bryostatins 
were originally isolated from the bryozoan Bugula neritina, and the bacterial symbiont of B. 
neritina appears to be responsible for bryostatin biosynthesis (see “Evidence for symbiotic 
origin of bryostatins” below). The B. neritina symbiosis represents one of the best 
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documented examples of bioactive metabolite symbiosis. In this model system, the 
ecological roles and biomedical potential of the compound are well described, and the 
symbiotic origin of the compound has been explored. This review provides an overview of 
the origin, biological context, and biotechnological prospects of bryostatins, and covers the 
period from 2005–2010.
Bryostatins: Discovery and structures
The bryostatins are a family of structurally related cyclic polyketides originally isolated 
from the marine bryozoan Bugula neritina (reviewed in [1]). All known bryostatins share a 
common macrolactone core with three tetrahydropyran rings (Figure 1); they differ 
predominantly in their substituents at C-7 and C-20 positions, and whether a γ-lactone ring 
is fused to the C-19 to C-23 tetrahydropyran ring. The bryostatins can also be categorized by 
the presence or absence of a 2,4-octadienoate moiety at their C-20 positions. The first 
bryostatins were discovered using an antineoplastic bioassay-guided fractionation approach 
[2]. Bryostatins are present in very low amounts in B. neritina colonies: nearly all of the 
bryostatins were isolated at a yield of 10−5 and 10−7 % B. neritina adult colony wet weight 
from various populations worldwide. Bryostatins 10 and 20 were isolated from B. neritina 
larvae, but at a thousand-fold higher concentration than the adult colonies, which suggests a 
significant role of these compounds in the larval stage of B. neritina. Additional bryostatins 
undoubtedly exist in nature. Using a bioassay, bryostatin activity was observed in a related 
bryozoan, B. simplex, and the presence of structurally similar but novel bryostatins was 
detected by chromatography and mass spectrometry [3]. Whether the structural diversity of 
bryostatins is related to biological function, environmental conditions or artifacts of isolation 
is not clear [4,5].
Clinical status of bryostatins
Most of the pharmacological and clinical research on bryostatins has focused on bryostatin 
1, which is noteworthy for its hydrophobic alkyl chain at C-20 (Figure 1). Bryostatins bind 
to the diacylglycerol binding site of the C-1 regulatory domain of protein kinase C (PKC); 
most, but not all, of bryostatins’ pharmacological effects are attributed to this interaction [6]. 
Protein kinase C (PKC) signaling pathways are involved in many regulatory processes in 
eukaryotic cells. PKC exists in ten isoforms that are differentially expressed in tissues, and 
variously regulated by diacylglycerol, calcium and phospholipid. Consequently, PKC 
activators, including bryostatins, have complex effects in animals, and these effects can vary 
greatly with concentration.
Bryostatins were first isolated due to their inhibition of the growth of murine P388 
lymphocytic leukemia cells in vitro and in vivo [2]. After more than thirty phase I and II 
clinical trials in a variety of cancers, alone and in combination with other chemotherapy 
agents, bryostatin 1 has not been effective enough to progress to phase III clinical trials as a 
cancer treatment. More recently, bryostatin 1 has been explored in other contexts. It shows 
promise in central nervous system applications [7]. In rodent models of learning, depression, 
stroke and Alzheimer’s disease, bryostatin 1 has produced striking positive results [8–13]. A 
human Alzheimer’s disease Phase II clinical trial has been initiated. Most recently, 
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bryostatin 1 has been proposed as a possible therapy for human immunodeficiency virus 
(HIV) [14]. Although current antiviral therapy is effective against HIV, the disease cannot 
be cured because latent viruses persist in resting cells. Based on in vitro studies, bryostatins 
may be effective in activating latent viruses so they can be purged from cellular reservoirs, 
exposed to antiviral therapy, and eliminated.
Poor availability of bryostatins has hindered clinical development. Mariculture of B. neritina 
has been accomplished, but has not been commercially implemented [15]. Although total 
synthesis of naturally occurring bryostatins has been achieved and is steadily being 
improved, it is not yet practical for industrial production [16]. Synthesis of simplified 
structural analogues of bryostatins is currently an active area of research [17,18]. Analogues 
that are more synthetically accessible, yet retain biological activity, have been attained and 
may ultimately prove clinically useful.
Bugula neritina
Bugula neritina, the source of all fully characterized bryostatins, is a marine bryozoan with a 
cosmopolitan distribution. Like other bryozoans, it is a colonial organism comprised of 
individual zooids (Figure 2A). Each feeding zooid in the colony possesses a lophophore, a 
ring of tentacles used to capture plankton from seawater (Figure 2B). Zooids in a colony are 
interconnected by a funicular system, which transports nutrients from feeding zooids to non-
feeding zooids and to the brood chambers called ovicells (Figure 2B) [19]. Embryos develop 
from fertilized eggs in the ovicells, and when mature, they are released as non-feeding 
larvae into the seawater (Figure 2C). B. neritina larvae typically settle on hard substrate, 
after which they metamorphose into the first feeding zooid, called the ancestrula. The 
ancestrula then reproduces asexually by budding to form a juvenile colony (Figure 2D).
Ecological role of bryostatins
The first hint that bryostatins may be significant to the ecology of B. neritina larvae came 
from a study using whole extracts of B. neritina adult and larvae in fish feeding assays [20]. 
The study demonstrated that adult extracts were palatable to generalist fish, while larval 
extracts were deterrent. Moreover, it was shown that when predators ingest B. neritina 
larvae, the larvae are regurgitated and their metamorphosis is not hindered [21]. A follow-up 
study identified bryostatins 10 and 20 as feeding deterrents when tested at concentrations 
found in the larvae [22,23]. Ontogenetic localization of bryostatins, using a unique 
fluorescence technique based on bryostatins’ PKC-binding activity, revealed that the 
bryostatins are delivered as a coating onto the developing embryo in the ovicell from 
bacterial aggregates via the funicular system [24]. Upon maturation and release, this “cloak” 
of bryostatins (Fig. 3E) remains on the larvae until two days after they settle on a substrate 
and begin metamorphosis. The loss of bryostatins not unexpectedly coincides with the 
synthesis of a chitin exoskeleton, which would physically protect juvenile B. neritina from 
predation. The data from the bryostatin localization corroborate previous research 
demonstrating ontogenetic changes in bioactivity during early B. neritina development [25].
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Discovery of symbionts
Before the discovery of bryostatins, B. neritina was the subject of numerous studies in 
developmental biology and natural history. In 1969, during an investigation of the 
microanatomy of several bryozoans, Lutaud observed the presence of rod-shaped bacteria in 
the funicular system of adult colonies of a Bugula species, B. turbinata [26]. To our 
knowledge, this was the first account of bacteria living within a bryozoan. Whether the 
observed bacteria are a monoculture or are a mixed community could not be determined 
from microscopic examination. Another microscopic investigation of larvae of different 
Bugula species revealed that B. neritina, B. pacifica and B. simplex contained rod-shaped 
bacteria in the larval pallial sinus [25]. Interestingly, the pallial sinuses of B. stolonifera and 
B. turrita are devoid of bacteria. The morphological similarities of the bacteria in adult B. 
turbinata observed by Lutaud [26] and in B. neritina, B. pacifica, and B. simplex larvae [27] 
hint at close evolutionary relationships among the bacteria; however, molecular methods 
were necessary to uncover the identities and relationships of the bacteria in the Bugula 
larvae.
Haygood and Davidson used bacterial small subunit (SSU, 16S) ribosomal RNA gene 
sequencing to identify bacteria in from B. neritina larvae collected in Southern California 
[28]. A specific oligonucleotide probe targeting the SSU rRNA sequence hybridizes to rod-
shaped bacterial cells in the pallial sinus of B. neritina larvae. Identical SSU rRNA sequence 
was found in all of the California populations tested in this study, while absent in a co-
occurring bryozoan, suggesting that bacterium in the pallial sinus engaged in a specific 
relationship with B. neritina. Co-hybridization of the specific probe and a universal bacterial 
probe demonstrates that both probes bind to all the bacterial cells, indicating the pallial sinus 
bacteria are a monoculture (Figure 3B). This bacterial symbiont was named “Candidatus 
Endobugula sertula.” The Candidatus designation is used for description of bacteria that 
have not been cultivated. Two strains of “Candidatus Endobugula sertula” are known (see 
discussion of sibling species of B. neritina below). The bacterial SSU rRNA sequences from 
the other symbiotic Bugula species were subsequently obtained and analyzed, and the results 
demonstrate that they are all closely related and form a unique bacterial group within the 
gamma proteobacteria, none of which has yet been cultivated [29].
Evidence for a symbiotic origin of bryostatins
The structure of the structurally and biosynthetically complex bryostatins is reminiscent of 
typical bacterial secondary metabolites, leading to the hypothesis that the symbiotic 
bacterium “Candidatus Endobugula sertula” carries out bryostatin biosynthesis. However, to 
move from speculation to confirmation of a microbial origin is challenging and requires 
rigorous experimental testing (reviewed in [30]). It is particularly challenging when the 
microbe is uncultivated.
Although definitive proof that the symbiont “Candidatus Endobugula sertula” is the 
producer of bryostatins is lacking, several lines of evidence support this hypothesis. Perhaps 
the most suggestive piece of evidence is the reduced bryostatin content in B. neritina 
colonies that developed from antibiotic-treated larvae [22,31]. The reduction in bryostatin 
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was concomitant with a reduction in “Candidatus Endobugula sertula” levels. In these two 
studies, the bryozoan host did not appear to be affected by the antibiotic treatment, however, 
the possibility that the observed decrease in bryostatins was due to the decrease of a cryptic 
symbiont cannot be eliminated.
Another line of evidence for a symbiotic origin of bryostatins stems from the discovery of B. 
neritina sibling species. There are three sibling species known to date: the Deep, Shallow 
[32]and Northern sibling species are readily distinguished by mitochondrial cytochrome 
oxidase I sequence [33] (Table 1). Because the taxonomy has not been revised, they are all 
still identified as Bugula neritina. The Deep sibling species is predominantly found in 
Southern Californian waters below 9 meters in depth, and contains bryostatins 1–3, (in 
addition to other bryostatins). These bryostatins share the 2,4-octadieonoate moiety at C-20, 
which is absent in the other bryostatins (Figure 1). The Shallow sibling species, which was 
further divided into the S1 and S2 genotypes by Mackie et al. [34], in contrast, does not 
contain bryostatins 1–3, but does contain the other bryostatins. The S1 genotype appears to 
have a cosmopolitan distribution and is considered an invasive species, while the S2 
genotype is restricted to California. Both the Deep and Shallow sibling species contain 
“Candidatus Endobugula sertula”, and the SSU rRNA sequence of “Candidatus Endobugula 
sertula” strains from Deep and Shallow sibling species differ by 4 bp. The Northern sibling 
species was found in coastal waters off Delaware and Connecticut; these animals do not 
appear to contain “Candidatus Endobugula sertula” or bryostatins [33]. Thus, the presence 
of bryostatins has always been correlated with the presence of “Candidatus Endobugula 
sertula”, supporting the hypothesis of a symbiotic origin of bryostatins.
Examination of the biosynthesis of bryostatins also provides evidence for the role of 
“Candidatus Endobugula sertula” in bryostatin production. The putative gene cluster, the 
bry cluster (described below), is proposed to produce “bryostatin 0”. Expression of mRNA 
from the cluster was detected by in situ hybridization in “Candidatus Endobugula sertula” 
cells in B. neritina larvae, and not in host cells [31]. Taken together, these three lines of 
evidence point to “Candidatus Endobugula sertula” as the producer of “bryostatin 0”.
Biosynthesis of bryostatins
Because “Candidatus Endobugula sertula” is as yet uncultivated, conventional biosynthetic 
studies using isotope labeling, mutants and in vitro studies of purified enzymes are not 
feasible. Kerr and coworkers purified radiochemically pure bryostatin 1 by incubating a B. 
neritina cell-free enzyme preparation with radiolabeled precursors. The authors showed the 
incorporation of acetate, glycerol, and SAM-adenosylmethionine, indicating these moieties 
as probable precursors of bryostatin biosynthesis [34].
Other inferences about bryostatin biosynthesis have been made from bioinformatic analyses. 
Modular polyketides synthases (PKS) consist of modules containing a set of catalytic 
domains for each extension cycle. Using primers based on conserved sequence signatures of 
modular PKS ketosynthase (KS) domains, a ketosynthase gene fragment that was 
consistently present in Shallow and Deep B. neritina metagenomic DNA was obtained [31]. 
The fragment was used to screen libraries prepared with metagenomic DNA isolated from 
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Shallow and Deep B. neritina and enriched in “Candidatus Endobugula sertula” DNA. 
Several PKS-encoding clones were obtained which, when sequenced, converged to a single 
genomic region with features of a bacterial gene cluster, named the bry cluster [31,35,36]. 
The bry cluster spans ~80Kb in size and contains two parts, both entirely conserved in both 
Shallow and Deep “Candidatus Endobugula sertula” strains; the bry cluster does not reveal 
the origin of the different bryostatin profiles among B. neritina sibling species. The two 
parts are a 71kb bryBCXDA PKS operon, formed by five giant type I PKS genes, and the 
6kb bryPQRS operon, with four smaller accessory genes (Figure 4) [36]. Genes for the 
oxidation of C-20 and modification of C-7 and C-20 have not been identified in the bry 
region. In the Deep “Candidatus Endobugula sertula” strain the two parts are not 
contiguous, while in the Shallow strain they form a unified and possibly ancestral locus 
(Figure 4). The three large identical sequence repeats in the bryBCXDA PKS operon must 
represent duplication events that would normally be resolved by recombination, suggesting 
that, like other obligate symbionts, “Candidatus Endobugula sertula” is recombination 
deficient.
Analysis of the order and sequence features of catalytic domains shows that bry cluster 
enzymes lack acyltransferase (AT) domains within modules, and thus belong to the class of 
trans-AT type I PKSs. Except for the enigmatic bryX, the predicted enzymatic reactions are 
strikingly correlated with the biosynthetic steps required for the synthesis of “bryostatin 0” 
(Figure 5) [35,36]. Particularly, the hypothesis of D-lactate starter unit formation by 
bryA_LM [35], the match between the introduction of gem-dimethyl groups with the 
location of methyltransferase (MT) domains in modules 4 and 9, as well as pyran ring 
formation with the pyran-synthase (PS) domain in module 8 [36] gave credence to the 
biosynthetic proposal (Figure 5). Moreover, recent in vitro characterization of BryP, the 
tandem-AT encoded by bryP, conclusively showed this enzyme’s ability to selectively 
acylate malonyl-CoA on native and heterologous acyl-carrier-protein (ACP) domains, as 
well as in entire trans-AT PKS modules, corroborating the proposed role of BryP in the 
trans-loading of all extending bry cluster modules [37].
Since the publication of the bry cluster, Piel’s group discovered that the KS domains of 
trans-AT PKSs can be grouped into types based on sequence similarity [38]. The types 
reflect the structure of the incoming precursor at the beta carbon, and thus the specific 
reaction catalyzed by the preceding module. Piel’s analysis [39] of the KS domains of the 
bry cluster supports the hypothesis proposed by Sudek et al. [36] that the bry cluster codes 
for “bryostatin 0” biosynthesis. In fact, only two biosynthetic steps were modified in the 
revised scheme, and these differences reflect the steps in which branching occurs in the acyl 
units loaded by the virtually identical modules 3 and 7 of the bryostatin route (respectively 
Bry_M3, and Bry_M7) [39]. In this analysis, the condensation of an acetyl-CoA moiety 
proposed to be catalyzed by the hydroxy-methyl-glutaryl-CoA synthase (HMG-CS), BryR, 
occurs on the β-keto group of loaded malonyl-CoA substrates, during chain elongation 
instead of after macrocyclization [39] (Figure 5B, substrates in red). This is in agreement 
with the grouping of BryKS4 and BryKS8 into the clade Ib (Figure 5A) for KS domains 
with specificity for β-branched substrates. Continuing advances in catalytic domain 
annotation are improving the tools for chemical structure predictions of trans-AT systems. 
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In the case of the bry cluster, these tools might be helpful in pinpointing the role of BryX, 
the PKS with an intriguingly aberrant catalytic domain constellation and with no obvious 
role in bryostatin precursor biosynthesis (Figures 4 and 5). However, bryX is completely 
conserved in bry clusters from both Deep and Shallow “Candidatus Endobugula sertula” 
strains, and is expressed in the symbiotic state, suggesting it is probably functional [36].
Challenges and opportunities in future research on bryostatins
While gaps remain in our understanding of the B. neritina-“Candidatus Endobugula sertula” 
system, it is perhaps the most well-rounded example of a bioactive metabolite symbiosis. 
The uncultivated symbiont has been identified by molecular methods, the bioactive 
metabolites are characterized, a probable biosynthetic pathway has been postulated, and the 
ecological underpinnings of the symbiosis have been established. However, there are still 
many questions that need to be addressed.
Cultivation of symbionts
Cultivation of “Candidatus Endobugula sertula” would facilitate bryostatin research, but 
may prove difficult or impossible. Over evolutionary time, obligate symbionts tend to 
undergo genomic degradation resulting in impaired recombination and repair, reduced 
genome size, increased AT content of the genome and loss of non-essential genes [40]. 
“Candidatus Endobugula sertula” appears to fall in the middle of the degradation spectrum. 
The AT content of the bry cluster is high, exceeding 70% in some regions. The large perfect 
repeats in the cluster suggest impaired recombination and repair. The genome size is 
approximately 2 Mb based on flow cytometry (C.M Anderson and M.G. Haygood, 
unpublished data), compared to 5 Mb for its close relative Teredinibacter turnerae [41]. 
Metabolic genes upstream of the bry cluster appear to be nonfunctional (C.M Anderson and 
M.G. Haygood, unpublished data). A genome size of 2 Mb, while small, does not 
necessarily preclude growth in free-living conditions. However, on the whole, the genome of 
“Candidatus Endobugula sertula” appears to be that of an obligate symbiont, which should 
be difficult to grow outside the host, since it would have poor adaptability to environmental 
change.
Expression of bry genes
Expressing the bry cluster in another host and producing an indisputable bryostatin 
precursor would be conclusive proof of the symbiotic origin of bryostatins. Such proof has 
been achieved in a different system via heterologous production of the patellamides, which 
are synthesized by the cyanobacterial symbiont Prochloron didemni in didemnid ascidians 
[42]. There are major obstacles to the heterologous expression of the bry cluster: i) the 
cluster size, which challenges any strategy for manipulation, ii) the bryA loading-module’s 
impressively high AT content (~70%), which renders this DNA segment highly unstable and 
toxic for commonly used expression vectors/hosts systems (eg, E. coli/Bacillus sp. 
expression vectors), iii) the large DNA repeats in the PKS operon, which favor 
recombination and collapse, finally iv) the mechanisms of expression regulation which are 
still obscure for bry cluster. However, major advances have been made in all steps of 
heterologous expression in the last decade, and similar issues have been overcome in other 
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systems. Manipulation of large DNA fragments for example, were achieved in the 
reconstitution of the myxothiazol gene cluster [43] and in the transfer of a 100Kb DNA 
segment in B. subtilis 168 [44]. Problems of DNA toxicity and codon usage bias, on the 
other hand, can be circumvented by de novo design and artificial DNA synthesis [45,46].
How is bryostatin biosynthesis regulated?
Several studies have documented the changes in bryostatin content across life stages in B. 
neritina [22,24,25], and regulatory regions have been identified upstream of the bryBCXDA 
operon (Christine M Anderson, PhD thesis, University of California, San Diego, 2006), but 
it is still unknown what factors regulate bryostatin biosynthesis in nature. It is also unclear if 
the increase in bryostatin content in the ovicells is due to a stoichiometric increase in 
“Candidatus Endobugula sertula” levels, or to density-dependent gene expression (ie, 
quorum sensing) of bryostatin biosynthetic genes. One tantalizing piece of evidence in 
support of the quorum sensing hypothesis is the lack of bryostatin signal in B. neritina 
juveniles which contain a small inoculum of “Candidatus Endobugula sertula”, and the 
subsequent colocalization of bryostatins with “Candidatus Endobugula sertula” when the 
population density of “Candidatus Endobugula sertula” increases [24]. It is also unclear if 
an intermediary host factor made by B. neritina is used to transduce the signal from the 
environment to the symbionts.
Bryostatin diversity
Though the genetic architecture of the bry cluster is consistent with that of the hypothetical 
compound, “bryostatin 0”, we still do not understand how this putative precursor is 
elaborated to form the 20 known bryostatins. While “bryostatin 0” appears to be 
symbiotically produced, it is possible that the oxidation of C-20, esterifications at C-7 and 
C-20, and the γ-lactone at C-19 and C-23, are the result of enzymatic modifications by the 
host bryozoan, other microbes or due to abiotic processes. One possible abiotic process was 
documented by Abadi et al. who detected esterification products, similar in structure to some 
bryostatins, by mass spectrometry when bryostatin 1 was incubated with a carboxylic acid 
[5]. Furthermore, investigation of the mechanism by which bryostatins are transported and 
attached to the larvae may reveal new and ecologically relevant bryostatin variants. 
Exploration of the relationships between B. neritina and its various predators and 
competitors in different habitats should also reveal new information about bryostatins’ 
structures, activities and regulation. For example a nudibranch predator of B. neritina on the 
U.S. West coast, Polycera atra, contains bryostatins in its body and egg masses (Seana K 
Davidson, PhD thesis, University of California, San Diego, 1999; Grace E Lim, PhD thesis, 
University of California, San Diego, 2004). Are these known or novel bryostatins, and do 
they function in chemical defense?
Summary
The Bugula-Endobugula-bryostatin system is a complex tapestry of biology, ecology, 
microbiology and chemistry that will continue to captivate researchers. Given the increasing 
interest in bryostatins for clinical use, both the synthetic and heterologous expression 
strategies for generating supplies sufficient of active compounds will likely be pursued. 
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Further insights gained from investigation of bryostatins in their natural biological context 
will advance marine biology as well as inform biotechnological studies.
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Figure 1. 
Structures of bryostatins “0”-20 (“bryostatin 0” is the hypothetical precursor to all the 
known bryostatins). Bryostatins which contain octa-2,4-dienoate moieties (in blue) are 
found only in the Deep B. neritina sibling species, whereas Shallow B. neritina contains 
bryostatins with other kinds of esterifications (in green). The oxygen groups highlighted in 
red represent the pharmacophoric elements involved in binding to PKC.
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Figure 2. 
(A) A typical colony of Bugula neritina, which consists of (B) zooids arranged biserially. 
Ovicells brood (C) ciliated non-feeding larvae, which settled on hard substrate and 
metamorphose into the first feeding zooid, called the ancestrula, which then reproduces by 
budding to form a (D) juvenile colony
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Figure 3. 
“Candidatus Endobugula sertula” and bryostatin localization in Bugula neritina larvae. (a) 
Bacteria in the pallial sinus of a Bugula neritina larva, as shown by simultaneous 
fluorescence in situ hybridization (FISH) with two probes – the general eubacterial probe 
CY5-EUB338 (red) and a specific CY3“Candidatus Endobugula sertula” probe (green) – 
shown as a composite of the two signals (yellow). Bar = 20 μm. The same image is shown in 
higher magnification in (b)–(d), where (b) is a high magnification image of the pallial sinus 
with both probes. The symbiont-specific probe (c) and EUB338 (d) hybridize to the same 
cells, indicating a monoculture of “Candidatus Endobugula sertula” in the larval pallial 
sinus. Bar = 5 μm. (e) A coating of the bryostatins (blue) is detected around the exterior of a 
B. neritina larva via the PKC-labeling method [24]. Also visible in the larval pallial sinus is 
the CY5-EUB338/CY3-“Candidatus Endobugula sertula” FISH signal (yellow). Bar = 50 
μm.
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Figure 4. 
The organization of the bry cluster. Light gray box and dotted line emphasize differences 
found in Deep and Shallow strains of “Candidatus Endobugula sertula”. Modular polyketide 
synthase genes are shown as open arrows while accessory functions, primary metabolism 
and transposase genes are shown as orange, dark gray and black arrows respectively. The 
three large DNA repeats in the bryBCXDA PKS operon are represented as light blue, gold 
and pink boxes. PKSs modules proposed to be involved in “bryostatin 0” assembling are 
shown as black bars and numbered according to their order of action. Adapted from [37].
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Figure 5. 
Proposed biosynthesis of bryostatins. A – BryKS domains’ substrate specificity. Except for 
the D-lactate starter unit, all hypothetically recognized substrates are highlighted in colors. B 
–precursor chain elongation. Added substrates are shown after modifications, highlighted 
following the color code presented in A. Catalytic domains are shown in gray or, when 
hypothesized to be inactive, in white bubbles. Acyl-carrier-protein domains are shown as 
small filled circles with growing chain attached by the thiol group. Two proteins with split 
modules are shown in pink. The box details the HMG-CoA synthase-driven acetyl-CoA 
condensation onto C13/C20 beta-keto groups. Abbreviations not included in review’s text: 
KR, ketoreductase; OMT, O – methyltransferase; ER, enoyl reductase; DH, dehydratase; C, 
condensation. DH* and KR* are respectively DH and KR-like domains involved in the 
biosynthesis of D-lactate starter unit from the3 carbon precursor loaded by the FkbH-like 
domain, as proposed [36].
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Table 1
Summary of symbiotic status and bryostatin content in B. neritina
Sibling species Location Symbiotic? Bryostatins? Reference
Deep (D) California (> 9 m depth) Yes Chemotype O [32]
Shallow (S1) Cosmopolitan Yes Chemotype M [50,32]
Shallow (S2) California (< 9 m depth) Yes Chemotype M [50,32]
Northern Delaware and Connecticut None detected None detected [33]
Chemotype O: includes bryostatin 1 and other C-20 2,4-octadienoate bryostatins plus other bryostatins; Chemotype M, lacks bryostatin 1 and other 
C-20 2,4-octadienoate bryostatins, but contains other bryostatins
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